Study of TRB-001 vaccine for Parkinson's disease after prior immunotherapy
Part of Brain & nervous system clinical trials.
This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Participants must be 18 years of age or older.
- Participants must have a diagnosis of Parkinson's disease (any stage).
- Participants must have previously received immunotherapy targeting alpha-synuclein.
- Participants must not be pregnant, breastfeeding, or of childbearing potential without using contraception.
- Participants must not have contraindications to MRI or lumbar puncture.
- Participants must not have autoimmune disease, active infections (hepatitis B/C, HIV), recent cancer, substance abuse, or unstable psychiatric conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
This trial tests an experimental drug called MT101-5 for people recently diagnosed with Parkinson's disease. It aims to see if the drug is safe and can help control symptoms.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.